Literature DB >> 23764040

Treatment of sleep disorders may improve fatigue in multiple sclerosis.

Christian Veauthier1, Gunnar Gaede, Helena Radbruch, Sandra Gottschalk, Klaus-Dieter Wernecke, Friedemann Paul.   

Abstract

OBJECTIVE: In a previous polysomnographic cross-sectional study we found a significant relationship between sleep disorders and multiple sclerosis (MS) related fatigue. The purpose of this open follow-up observation was to compare the impact of treatment of sleep disorders on MS related fatigue measured with the Modified Fatigue Impact Scale (MFIS).
METHODS: Non-randomized follow-up observation: treated versus untreated patients, subgroups according to compliance with sleep medical treatment recommendations (univariate, multivariate analysis, multiple logistic regression). 66 MS patients were followed after polysomnography, 49 patients with relevant sleep disorders and 17 without.
RESULTS: Mean MFIS scores decreased from 41.2 to 26.2 (p=0.025) in patients with good compliance (GC; n=18), from 42.4 to 32.1 (p=0.12) in patients with moderate compliance (MC; n=12), and from 41.6 to 35.5 (p=0.17) in non-compliant patients (NC; n=17). Mean MFIS values increased in patients without sleep disorders from 22.9 to 25.4 (NSD; n=12, p=0.56). In multiple logistic regression, treatment of sleep disorders predicted decrease of MFIS-values (GC versus NSD odds ratio 13.4; p=0.015; 95% confidence interval (CI) 1.7-107.2, MC versus NSD odds ratio 13.8; p=0.028; 95% CI 1.3-143.3).
CONCLUSIONS: Sleep medical treatment may improve MS related fatigue when patients adhere to treatment recommendations.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fatigue; Modified Fatigue Impact Scale; Multiple sclerosis; Polysomnography; Sleep disorders

Mesh:

Year:  2013        PMID: 23764040     DOI: 10.1016/j.clineuro.2013.05.018

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  26 in total

Review 1.  [Sleep disorders in neurological diseases].

Authors:  S Kotterba
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

2.  Sleep and oligodendrocyte functions.

Authors:  Michele Bellesi
Journal:  Curr Sleep Med Rep       Date:  2015-03-01

3.  Central sleep apnea in multiple sclerosis: a pilot study.

Authors:  Michael Lin; Arun V Krishnan; Danny J Eckert
Journal:  Sleep Breath       Date:  2016-12-14       Impact factor: 2.816

4.  Feasibility and treatment effect of cognitive behavioral therapy for insomnia in individuals with multiple sclerosis: A pilot randomized controlled trial.

Authors:  Catherine F Siengsukon; Mohammed Alshehri; Cierra Williams; Michelle Drerup; Sharon Lynch
Journal:  Mult Scler Relat Disord       Date:  2020-01-23       Impact factor: 4.339

5.  Sleep disorders in patients with multiple sclerosis.

Authors:  Zuzana Čarnická; Branislav Kollár; Pavel Šiarnik; Lucia Krížová; Katarína Klobučníková; Peter Turčáni
Journal:  J Clin Sleep Med       Date:  2015-04-15       Impact factor: 4.062

Review 6.  Sleep disorders in multiple sclerosis. Review.

Authors:  Christian Veauthier
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

Review 7.  [Therapy of fatigue in multiple sclerosis : A treatment algorithm].

Authors:  C Veauthier; F Paul
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

Review 8.  A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis.

Authors:  Tiffany J Braley; Ronald D Chervin
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 9.  Fatigue as a symptom or comorbidity of neurological diseases.

Authors:  Iris-Katharina Penner; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2017-10-13       Impact factor: 42.937

10.  Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis.

Authors:  Cristina Fernandez-Carbonell; Leigh E Charvet; Lauren B Krupp
Journal:  Paediatr Drugs       Date:  2021-05-17       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.